|
시장보고서
상품코드
2115777
백신 시장 예측(-2031년) : 적응 질환별, 기술별, 유형별, 투여 경로별, 최종사용자별, 지역별Vaccines Market by Technology, Type, Disease, ROA, Competition - Global Forecast to 2031 |
||||||
백신 시장 규모(COVID-19 제외)는 2026년 556억 8,000만 달러에서 2031년에는 711억 4,000만 달러에 달할 것으로 예상되고 있으며, 예측 기간 중 CAGR 5.0%로 성장할 것으로 전망되고 있습니다.
| 조사 범위 | |
|---|---|
| 조사 대상 기간 | 2026-2031년 |
| 기준연도 | 2025년 |
| 예측 기간 | 2026-2031년 |
| 산정 단위 | 금액(10억 달러) |
| 부문 | 적응 질환별, 기술별, 유형별, 투여 경로별, 최종사용자별, 지역별 |
| 대상 지역 | 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카 |
전염병의 높은 발생률, 백신 기술의 혁신, 백신 개발에 대한 정부의 지원 및 막대한 자금 지원, 예방접종 노력의 확대, 그리고 혁신적인 제품에 대한 투자와 출시를 위한 강력한 집중과 같은 요인들이 백신 시장의 성장을 주도하고 있습니다.
질병별로는 2025년에 폐렴구균 백신 부문이 백신 시장에서 가장 큰 점유율을 차지했습니다.
질병별로는 백신 시장이 혼합 백신, HPV, 수막구균 감염증, 대상포진, 로타바이러스, MMR, 폐렴구균 감염증, 인플루엔자, 수두, 간염, DTP, 소아마비, COVID-19 및 기타 질병으로 분류됩니다. 2025년, 폐렴구균 부문은 백신 시장에서 가장 큰 점유율을 차지했습니다. 이는 전 세계 폐렴구균 감염증 발생률의 증가, 예방접종 프로그램에 대한 정부 자금 지원 확대, 그리고 폐렴, 수막염, 혈류 감염과 같은 폐렴구균 관련 합병증으로 인한 심각한 건강 위험에 대한 일반 대중의 인식 제고 등 몇 가지 중요한 요인에 기인합니다. 또한 지속적인 기술 혁신과 최근 승인된 20가 및 21가 접합백신과 같은 차세대 폐렴구균 백신의 개발로 예방접종 선택의 폭이 넓어지면서 시장 성장과 공중보건상 이점이 더욱 촉진되고 있습니다.
유형별로는 2025년 백신 시장에서 다가 백신 부문이 가장 큰 점유율을 차지했습니다.
백신 시장은 유형에 따라 단가 백신과 다가 백신으로 분류됩니다. 2025년에는 다가 백신 부문이 백신 시장에서 가장 큰 점유율을 차지했습니다. 이러한 우위는 다가 백신이 1회 접종으로 여러 질병으로부터 보호할 수 있다는 점에 기인합니다. 이로 인해 필요한 주사 횟수가 줄어들고 예방접종이 간소화되어 환자의 순응도가 향상되며, 물류상의 문제도 완화됩니다. 또한 호흡기 감염증이나 특정 암 등 광범위한 면역이 필요한 질환의 유병률이 증가하고 있는 점도 이러한 백신에 대한 수요를 높이고 있습니다. 이러한 추세를 더욱 지원하고 있는 것은 다가 백신의 효율적인 제조를 위한 기술 발전과 투자 확대이며, 이를 통해 더 대규모적이고 신속한 생산이 가능해졌습니다. 의료 접근성이 제한된 지역의 정부와 의료 제공자들은 예방접종 일정의 간소화가 접종률 향상과 공중보건 성과 개선으로 이어지기 때문에 특히 다가 백신을 선호하여 도입하고 있습니다.
2026-2031년에 백신 시장에서 아시아태평양이 가장 높은 연평균 성장률(CAGR)을 기록할 것으로 예상됩니다.
백신 시장은 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카으로 분류됩니다. 아시아태평양은 예측 기간 중 상당한 연평균 성장률(CAGR)을 기록할 것으로 예상됩니다. 이러한 성장은 공중 보건에 대한 의식의 향상, 국가 예방접종 프로그램의 확대, 그리고 의료 인프라에 대한 정부 투자의 증가에 의해 주도되고 있습니다. 이러한 노력을 지원하는 것은 민관 협력, 백신 접근성 향상을 목표로 한 국제 협력, 그리고 첨단 백신 개발과 보다 저렴한 가격의 생산을 가능하게 하는 기술 발전입니다. 또한 이 지역, 특히 중국과 인도 등 국가의 대규모이며 지속적으로 증가하는 인구는 기존 백신과 신규 백신 모두에게 큰 목표 시장이 되고 있습니다. 이러한 요인들은 백신 산업 시장에서 아시아태평양의 주도적인 위치를 부각시키고 있습니다.
Pfizer, Inc.(미국), GSK Plc(영국), Merck & Co., Inc.(미국), Sanofi(프랑스), CSL(호주), Emergent(미국), Johnson & Johnson Services Inc.(미국), AstraZeneca(영국),Serum Institute of India Pvt. Ltd.(인도), Bavarian Nordic(덴마크), Mitsubishi Tanabe Pharma Corporation(일본), Daiichi Sankyo Company, Limited(일본), Panacea Biotec(인도), Biological E. Limited(인도),Bharat Biotech(인도), Novavax(미국), Inovio Pharmaceuticals(미국), Sinovac(중국), Incepta Pharmaceuticals(방글라데시), Valneva SE(프랑스), VBI Vaccines Inc.(미국), Bio Farma(인도네시아),FSUE NPO Microgen(러시아), Zhi Fei Biological(중국), Indian Immunologicals Ltd.(인도) 등이 백신을 공급하고 있는 주요 기업의 일부입니다.
조사 범위
본 조사 보고서에서는 백신 시장을 기술별(접합백신, 재조합 백신, 불활성화·서브유닛 백신, 약독생백신, 토코이드 백신, 기타 백신), 유형별(단가 백신 및 다가 백신), 적응증별(폐렴구균 감염증, 인플루엔자, 혼합 백신,HPV, 수막구균 감염증, 대상포진, 로타바이러스, MMR, 수두, 간염, DTP, 소아마비, RSV, COVID-19 및 기타 질병 적응증),투여 경로(근육 내·피하 투여, 경구 투여 및 기타 투여 경로), 최종사용자(소아용 백신 및 성인용 백신), 그리고 지역(북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카)별로 분류하고 있습니다.
이 보고서의 조사 범위에는 백신 시장의 성장에 영향을 미치는 주요 요인(촉진요인, 과제, 기회, 제약 등)에 대한 상세한 정보가 포함되어 있습니다. 주요 업계 플레이어에 대한 포괄적인 분석을 수행하여, 사업 개요, 제품 포트폴리오, 그리고 제휴, 파트너십, 사업 확장, 계약, 인수, 백신 시장과 관련된 최근 동향을 포함한 주요 전략에 대한 인사이트를 제공합니다. 이 보고서에는 백신 시장 생태계내 주요 기업 및 신생 스타트업 기업의 경쟁 분석도 포함되어 있습니다. 또한 이 보고서에서는 시장 성장을 형성하는 촉진요인, 제약 요인, 과제, 기회와 같은 주요 요인에 대해 상세히 설명하는 한편, 주요 업계 기업의 솔루션, 제품, 최근 제품 출시, 합병, 인수 및 신흥 시장의 동향과 생태계에 대한 상세한 검토도 수록하고 있습니다.
이 보고서 구매의 주요 이점
이 보고서는 백신 시장에 대한 포괄적인 개요를 제공합니다. 기술, 유형, 적응증, 투여 경로, 최종사용자, 지역 등 다양한 부문에 걸친 시장 규모와 미래 성장 기회를 평가하는 것을 목표로 합니다. 또한 주요 시장 참여자에 대한 상세한 경쟁 분석도 수록되어 있으며, 각 기업의 프로필, 최근 동향, 주요 시장 전략 등이 포함되어 있습니다.
이 보고서는 다음 사항에 대한 인사이트를 제공합니다. :
주요 촉진요인(백신 개발 및 출시, 감염병 유행 확산, 예방접종 프로그램 확대, 백신 기술 발전, 백신 개발에 대한 정부의 지원 및 자금 제공에 초점을 맞춘 분석),제약 요인(백신 개발의 높은 비용), 기회(치료용 백신에 대한 관심 증가, 백신에 대한 광범위한 연구개발, 임상 시험에 대한 투자 증가) 및 과제(엄격한 규제 절차 및 제품 리콜)에 대한 분석
- 제품 개발/혁신: 신규 출시 제품에 대한 상세한 분석 및 백신 시장의 기술적 평가.
- 시장 개발: 수익성이 높은 시장에 대한 포괄적인 정보. 이 보고서에서는 다양한 지역에 걸친 백신 시장을 분석하고 있습니다.
- 시장 다각화: 백신 시장의 신규 및 미개발 지역, 최근 동향, 그리고 투자에 관한 포괄적인 정보
경쟁 분석: Pfizer, Inc.(미국), GSK Plc(영국), Merck & Co., Inc.(미국), Sanofi(프랑스), CSL(호주), Emergent(미국), Johnson & Johnson Services Inc.(미국), AstraZeneca(영국),Serum Institute of India Pvt. Ltd.(인도), Bavarian Nordic(덴마크), Mitsubishi Tanabe Pharma Corporation(일본), Daiichi Sankyo Company, Limited(일본), Panacea Biotec(인도), Biological E. Limited(인도),Bharat Biotech(인도), Novavax(미국), Inovio Pharmaceuticals(미국), Sinovac(중국), Incepta Pharmaceuticals(방글라데시), Valneva SE(프랑스), VBI Vaccines Inc.(미국), Bio Farma(인도네시아),FSUE NPO Microgen(러시아), Zhi Fei Biological(중국), Indian Immunologicals Ltd.(인도) 등이 있습니다.
또한 이 보고서는 이해관계자들이 백신 시장의 동향을 이해하는 데 도움을 주며, 주요 시장 촉진요인, 제약, 과제 및 기회에 대한 정보를 제공합니다. 주요 업계 플레이어에 대한 상세한 분석을 통해 주요 전략, 제품 출시 및 승인, 파이프라인 개발 현황, 인수, 제휴, 합작 투자, 최근 활동, 투자 및 자금 조달, 브랜드 및 제품 비교, 공급업체 평가, 그리고 백신 시장의 재무 지표에 대한 인사이트를 제공합니다.
자주 묻는 질문
목차
제1장 서론
제2장 개요
제3장 주요 인사이트
제4장 시장 개요
제5장 업계 동향
제6장 기술 진보, AI에 의한 영향, 특허, 그리고 혁신
제7장 규제 상황과 지속가능성 구상
제8장 고객 상황과 구매 행동
제9장 백신 시장, 적응 질환별
제10장 백신 시장, 기술별
제11장 백신 시장(COVID-19 백신 제외), 유형별
제12장 백신 시장(COVID-19 백신 제외), 투여 경로별
제13장 백신 시장(COVID-19 백신 제외), 최종사용자별
제14장 백신 시장(COVID-19 백신 제외), 지역별
제15장 경쟁 구도
제16장 기업 개요
제17장 조사 방법
제18장 부록
KSA 26.08.27The vaccines market (excluding COVID-19) is expected to reach USD 71.14 billion in 2031, up from USD 55.68 billion in 2026, growing at a CAGR of 5.0% during the forecast period.
| Scope of the Report | |
|---|---|
| Years Considered for the Study | 2026-2031 |
| Base Year | 2025 |
| Forecast Period | 2026-2031 |
| Units Considered | Value (USD billion) |
| Segments | Technology, Type, Disease Indication, Route of Administration, End User, and Region |
| Regions covered | North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa |
Factors such as the high incidence of contagious diseases, innovation in vaccine technology, government support and substantial funding for vaccine development, increasing vaccination initiatives, and a strong focus on investing in and launching innovative products are driving this growth in vaccines.
By disease indication, the pneumococcal segment accounted for the largest share of the vaccines market in 2025.
Based on disease indication, the vaccines market is segmented into combination vaccines, HPV, meningococcal disease, herpes zoster, rotavirus, MMR, pneumococcal disease, influenza, varicella, hepatitis, DTP, polio, COVID-19, and other disease indications. In 2025, the pneumococcal segment held the largest share of the vaccines market. This is due to several key factors: a rising incidence of pneumococcal infections worldwide; increased government funding for vaccination programs; and heightened public awareness of the serious health risks associated with pneumococcal-related complications such as pneumonia, meningitis, and bloodstream infections. Additionally, ongoing innovation and the development of next-generation pneumococcal vaccines, such as the recently approved 20-valent and 21-valent conjugate vaccines, are expanding immunization options, further boosting market growth and public health benefits.
By type, the multivalent vaccines segment accounted for the largest share of the vaccines market in 2025.
The vaccines market is divided into monovalent vaccines and multivalent vaccines, based on type. In 2025, the multivalent vaccines segment held the largest portion of the Vaccines market. This dominance stems from multivalent vaccines' ability to protect against multiple diseases with a single dose-simplifying immunization by reducing the number of injections needed, which increases patient compliance and decreases logistical challenges. Additionally, the growing prevalence of diseases that require broad-spectrum immunity, such as respiratory infections and certain cancers, has increased demand for these vaccines. Further supporting this trend are technological advances and increased investment in efficient manufacturing of multivalent vaccines, enabling larger and faster production. Governments and healthcare providers in regions with limited healthcare access particularly favor them because simplified vaccination schedules improve coverage and boost public health outcomes.
The Asia Pacific region is expected to grow at the highest CAGR in the vaccines market from 2026 to 2031.
The vaccines market region is divided into North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. The Asia Pacific region is expected to grow at a significant CAGR during the forecast period. This increase is driven by greater public health awareness, expanding national immunization programs, and increased government investment in healthcare infrastructure. Supporting these efforts are public-private partnerships, international collaborations aimed at improving vaccine equity, and technological advancements that enable advanced vaccine development and more affordable production. Additionally, the region's large and growing populations, especially in countries such as China and India, present a substantial target market for both established and new vaccines. These factors highlight the Asia Pacific's leadership in the vaccine industry market.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side (80%) and Demand Side (20%)
- By Designation: Managers (45%), CXOs and Directors (30%), and Executives (25%)
- By Region: North America (40%), Europe (25%), Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%)
Pfizer, Inc. (US), GSK Plc (UK), Merck & Co., Inc. (US), Sanofi (France), CSL (Australia), Emergent (US), Johnson & Johnson Services Inc. (US), AstraZeneca (UK), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo Company, Limited (Japan), Panacea Biotec (India), Biological E. Limited (India), Bharat Biotech (India), Novavax (US), Inovio Pharmaceuticals (US), Sinovac (China), Incepta Pharmaceuticals (Bangladesh), Valneva SE (France), VBI Vaccines Inc. (US), Bio Farma (Indonesia), FSUE NPO Microgen (Russia), Zhi Fei Biological (China), and Indian Immunologicals Ltd. (India) are some of the key companies offering vaccines.
Research Coverage
This research report categorizes the vaccines market by technology (conjugate vaccines, recombinant vaccines, inactivated & subunit vaccines, live attenuated vaccines, toxoid vaccines, and other vaccines), type (monovalent vaccines and multivalent vaccines), indication (pneumococcal disease, influenza, combination vaccines, HPV, meningococcal disease, herpes zoster, rotavirus, MMR, varicella, hepatitis, DTP, polio, RSV, COVID-19, and other disease indications), route of administration (intramuscular & subcutaneous administration, oral administration, and other routes of administration), end user (pediatric vaccines and adult vaccines), and region (North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa).
The scope of the report provides detailed information on major factors such as drivers, challenges, opportunities, and restraints that influence the growth of the vaccines market. A comprehensive analysis of key industry players has been conducted to offer insights into their business overview, product portfolios, and key strategies, including collaborations, partnerships, expansions, agreements, acquisitions, and recent developments related to the vaccines market. This report includes a competitive analysis of top players and upcoming startups within the vaccines market ecosystem. The report also details primary factors like drivers, restraints, challenges, and opportunities shaping the market growth, along with an in-depth review of key industry players' solutions, products, recent product launches, mergers, acquisitions, and emerging market trends ecosystem.
Key Benefits of Buying the Report
This report offers a comprehensive overview of the vaccines market. It aims to assess the size and future growth opportunities of the market across various segments, such as technology, type, indication, route of administration, end user, and region. The report also features an in-depth competitive analysis of the major market players, including their company profiles, recent developments, and key market strategies.
The report provides insights into the following pointers:
Analysis of key drivers (focus on vaccine development and launches, rising prevalence of infectious diseases, increasing immunization programs, advancements in vaccine technology, and government support & funding for vaccine development), restraints (high cost of vaccine development), opportunities (rising focus on therapeutic vaccines, extensive R&D for vaccines, and increased investments in clinical trials), and challenges (stringent regulatory processes and product recalls)
- Product Development/Innovation: Detailed insights on newly launched products and technological assessment of the vaccines market.
- Market Development: Comprehensive information about lucrative markets; the report analyzes the vaccines market across varied regions.
- Market Diversification: Exhaustive information about new, untapped geographies, recent developments, and investments in the vaccines market
Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as GSK plc (UK), Merck & Co., Inc. (US), Pfizer, Inc. (US), Sanofi (France), CSL (Australia), Emergent (US), Johnson & Johnson Services Inc. (US), AstraZeneca (UK), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo Company, Limited (Japan), Panacea Biotec (India), Biological E. Limited (India), Bharat Biotech (India), Novavax (US), Inovio Pharmaceuticals (US), Sinovac (China), Incepta Pharmaceuticals (Bangladesh), Valneva SE (France), VBI Vaccines Inc. (US), Bio Farma (Indonesia), FSUE NPO Microgen (Russia), Zhi Fei Biological (China), and Indian Immunologicals Ltd (India), among others, in the vaccines market.
The report also helps stakeholders understand the trends of the vaccines market and provides information on key market drivers, restraints, challenges, and opportunities. A detailed analysis of key industry players has been conducted to offer insights into their key strategies, product launches and approvals, pipeline developments, acquisitions, partnerships, collaborations, recent activities, investments and funding, brand and product comparisons, vendor evaluations, and financial metrics of the vaccines market.
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 STUDY SCOPE
- 1.3.1 MARKET SEGMENTATION & REGIONS COVERED
- 1.3.2 INCLUSIONS & EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
- 1.3.4 CURRENCY CONSIDERED
- 1.4 STAKEHOLDERS
- 1.5 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
- 2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
- 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
- 2.3 DISRUPTIVE TRENDS IN VACCINES MARKET
- 2.4 HIGH-GROWTH SEGMENTS
- 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
- 3.1 VACCINES MARKET OVERVIEW
- 3.2 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE AND COUNTRY, 2025
- 3.3 VACCINES MARKET (EXCLUDING COVID-19 VACCINES): GEOGRAPHIC GROWTH OPPORTUNITIES
- 3.4 VACCINES MARKET (EXCLUDING COVID-19 VACCINES) SHARE, BY ROUTE OF ADMINISTRATION, 2026 VS 2031 (%)
4 MARKET OVERVIEW
- 4.1 INTRODUCTION
- 4.2 MARKET DYNAMICS
- 4.2.1 DRIVERS
- 4.2.1.1 Focus on vaccine development and launches
- 4.2.1.2 Rising prevalence of infectious diseases
- 4.2.1.3 Increasing immunization programs
- 4.2.1.4 Advancements in vaccine technology
- 4.2.1.5 Government support and funding for vaccine development
- 4.2.2 RESTRAINTS
- 4.2.2.1 High cost of vaccine development
- 4.2.3 OPPORTUNITIES
- 4.2.3.1 Rising focus on therapeutic vaccines
- 4.2.3.2 Extensive R&D for vaccines and increased investments in clinical trials
- 4.2.4 CHALLENGES
- 4.2.4.1 Stringent regulatory processes
- 4.2.4.2 Product recalls
- 4.2.1 DRIVERS
- 4.3 UNMET NEEDS & WHITE SPACES
- 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
- 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5 INDUSTRY TRENDS
- 5.1 PORTER'S FIVE FORCES ANALYSIS
- 5.1.1 BARGAINING POWER OF SUPPLIERS
- 5.1.2 BARGAINING POWER OF BUYERS
- 5.1.3 THREAT OF NEW ENTRANTS
- 5.1.4 THREAT OF SUBSTITUTES
- 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.2 MACROECONOMIC OUTLOOK
- 5.2.1 INTRODUCTION
- 5.2.2 GDP TRENDS & FORECAST
- 5.2.3 TRENDS IN GLOBAL VACCINES INDUSTRY
- 5.3 VALUE CHAIN ANALYSIS
- 5.4 PIPELINE ANALYSIS
- 5.4.1 VACCINES MARKET: CLINICAL TRIALS, BY PHASE
- 5.4.2 VACCINES MARKET: CLINICAL TRIALS, BY DISEASE INDICATION
- 5.4.3 VACCINES MARKET: PHASE 2/3 CLINICAL TRIALS, BY COMPANY
- 5.5 ECOSYSTEM ANALYSIS
- 5.6 PRICING ANALYSIS
- 5.6.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER, 2024-2026
- 5.6.2 AVERAGE SELLING PRICE TREND, BY DISEASE INDICATION, 2024-2026
- 5.6.3 AVERAGE SELLING PRICE TREND, BY REGION, 2022-2024
- 5.7 TRADE ANALYSIS
- 5.7.1 IMPORT SCENARIO (HS CODE 300220)
- 5.7.2 EXPORT SCENARIO (HS CODE 300220)
- 5.8 KEY CONFERENCES AND EVENTS, 2026-2027
- 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESS
- 5.10 INVESTMENT AND FUNDING SCENARIO
- 5.10.1 VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE
- 5.11 IMPACT OF 2025 US TARIFFS-VACCINES MARKET
- 5.11.1 INTRODUCTION
- 5.11.2 KEY TARIFF RATES
- 5.11.3 PRICE IMPACT ANALYSIS
- 5.11.4 IMPACT ON COUNTRIES/REGIONS
- 5.11.4.1 US
- 5.11.4.2 Europe
- 5.11.4.3 Asia Pacific
- 5.11.5 IMPACT ON END-USE INDUSTRIES
- 5.11.5.1 Public health & government bodies
- 5.11.5.2 Healthcare providers & institutions
- 5.12 VACCINE PROCUREMENT DATA
- 5.12.1 NUMBER OF VACCINES DELIVERED BY UNICEF, 2024-2026
- 5.12.2 WHO: VACCINE PURCHASE DATABASE, 2022-2024
- 5.13 VACCINE MANUFACTURING PROCESS
- 5.13.1 OVERVIEW
- 5.13.1.1 R&D and process development
- 5.13.1.2 Upstream production (antigen generation)
- 5.13.1.3 Downstream processing
- 5.13.1.4 Formulation & fill-finish
- 5.13.1.5 Quality control & regulatory release
- 5.13.1.6 Packaging, cold chain, and distribution
- 5.13.2 MANUFACTURING MODELS & CAPACITY DYNAMICS
- 5.13.1 OVERVIEW
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, AND INNOVATIONS
- 6.1 TECHNOLOGY ANALYSIS
- 6.1.1 KEY EMERGING TECHNOLOGIES
- 6.1.1.1 Recombinant technology
- 6.1.1.2 Conjugation technology
- 6.1.1.3 Viral vector technology
- 6.1.2 COMPLEMENTARY TECHNOLOGIES
- 6.1.2.1 Encapsulation & delivery technology
- 6.1.2.2 Automation & control
- 6.1.2.3 AI & machine learning for vaccine design
- 6.1.3 ADJACENT TECHNOLOGIES
- 6.1.3.1 Single-use technology
- 6.1.3.2 Cell line development
- 6.1.1 KEY EMERGING TECHNOLOGIES
- 6.2 TECHNOLOGY/PRODUCT ROADMAP
- 6.3 PATENT ANALYSIS
- 6.3.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR VACCINE PATENTS
- 6.4 FUTURE APPLICATIONS
- 6.5 IMPACT OF AI/GEN AI-VACCINES MARKET
- 6.5.1 BEST PRACTICES IN VACCINES WORKFLOW
- 6.5.2 CASE STUDIES OF AI IMPLEMENTATION IN VACCINES MARKET
- 6.5.3 INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS
- 6.5.4 CLIENTS' READINESS TO ADOPT GENERATIVE AI IN VACCINES MARKET
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES
- 7.1 REGIONAL REGULATIONS AND COMPLIANCE
- 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 7.1.2 REGULATORY FRAMEWORK
- 7.1.2.1 North America
- 7.1.2.2 Europe
- 7.1.2.3 Asia Pacific
- 7.1.2.4 Latin America
- 7.1.2.5 Middle East & Africa
- 7.1.3 REGULATORY CHALLENGES IN VACCINES MARKET
- 7.1.4 INDUSTRY STANDARDS
- 7.2 SUSTAINABILITY INITIATIVES
- 7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY
- 7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
- 8.1 DECISION-MAKING PROCESS
- 8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
- 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 8.2.2 KEY BUYING CRITERIA, BY END USER
- 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
- 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
- 8.5 MARKET PROFITABILITY
9 VACCINES MARKET, BY DISEASE INDICATION
- 9.1 INTRODUCTION
- 9.2 PNEUMOCOCCAL DISEASE
- 9.2.1 EXPANDING ADULT IMMUNIZATION PROGRAMS AND HIGHER-VALENCY VACCINES TO DRIVE MARKET
- 9.3 INFLUENZA
- 9.3.1 SEASONAL IMMUNIZATION PROGRAMS AND EXPANDING ADULT VACCINATION TO DRIVE MARKET
- 9.4 HPV
- 9.4.1 EXPANDING NATIONAL HPV IMMUNIZATION PROGRAMS AND RISING ADOPTION OF GENDER-NEUTRAL VACCINATION TO DRIVE THE FASTEST-GROWING SEGMENT
- 9.5 HERPES ZOSTER
- 9.5.1 RISING AGING POPULATION TO DRIVE DEMAND FOR HERPES ZOSTER VACCINES
- 9.6 COMBINATION VACCINES
- 9.6.1 EXPANDING NATIONAL IMMUNIZATION PROGRAMS AND GROWING PREFERENCE FOR MULTI-ANTIGEN VACCINES TO DRIVE MARKET
- 9.7 MENINGOCOCCAL DISEASE
- 9.7.1 EXPANDING IMMUNIZATION RECOMMENDATIONS AND BROADER SEROGROUP COVERAGE TO SUPPORT MARKET GROWTH
- 9.8 ROTAVIRUS
- 9.8.1 RISING INFANT IMMUNIZATION PROGRAMS TO DRIVE ROTAVIRUS MARKET GROWTH
- 9.9 RSV
- 9.9.1 INITIAL VACCINE UPTAKE AND EXPANDING IMMUNIZATION RECOMMENDATIONS SUPPORT MARKET PENETRATION
- 9.10 DTP
- 9.10.1 CONTINUED ROUTINE CHILDHOOD IMMUNIZATION AND BOOSTER VACCINATION PROGRAMS TO SUPPORT MARKET
- 9.11 HEPATITIS
- 9.11.1 EXPANDING HEPATITIS B IMMUNIZATION AND GLOBAL ELIMINATION INITIATIVES TO SUPPORT MARKET GROWTH
- 9.12 VARICELLA
- 9.12.1 EXPANDING CHILDHOOD IMMUNIZATION PROGRAMS AND INCREASING ADOPTION OF VARICELLA VACCINES TO SUPPORT MARKET GROWTH
- 9.13 MMR
- 9.13.1 RISING MEASLES OUTBREAKS AND IMMUNIZATION RECOVERY EFFORTS TO SUPPORT MARKET GROWTH
- 9.14 POLIO
- 9.14.1 GLOBAL POLIO ERADICATION INITIATIVES AND CONTINUED VACCINATION CAMPAIGNS TO SUSTAIN MARKET DEMAND
- 9.15 COVID-19
- 9.15.1 SHIFT FROM PANDEMIC-DRIVEN DEMAND TO ENDURING HIGH-RISK POPULATION VACCINATION, RESULTING IN MARKET NORMALIZATION
- 9.16 OTHER DISEASE INDICATIONS
10 VACCINES MARKET, BY TECHNOLOGY
- 10.1 INTRODUCTION
- 10.2 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY
- 10.2.1 RECOMBINANT VACCINES
- 10.2.1.1 Broader adult immunization and continued recombinant vaccine launches to drive market
- 10.2.2 CONJUGATE VACCINES
- 10.2.2.1 Higher-valency pneumococcal vaccines and large public immunization programs to drive market
- 10.2.3 INACTIVATED & SUBUNIT VACCINES
- 10.2.3.1 Recurring influenza demand and wider access to established non-live vaccines to support market
- 10.2.4 LIVE ATTENUATED VACCINES
- 10.2.4.1 Durable immune protection and convenient oral or nasal administration to support market
- 10.2.5 TOXOID VACCINES
- 10.2.5.1 Routine pediatric boosters and maternal immunization programs to sustain market
- 10.2.6 OTHER VACCINES
- 10.2.1 RECOMBINANT VACCINES
- 10.3 COVID-19 VACCINES MARKET, BY TECHNOLOGY
- 10.3.1 MRNA VACCINES
- 10.3.1.1 Rapid variant adaptation and continued vaccination of high-risk populations to drive market
- 10.3.2 VIRAL VECTOR VACCINES
- 10.3.2.1 Withdrawal of first-generation products and shift toward updated vaccine platforms to accelerate market decline
- 10.3.3 OTHER COVID-19 VACCINES
- 10.3.1 MRNA VACCINES
11 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE
- 11.1 INTRODUCTION
- 11.2 MULTIVALENT VACCINES
- 11.2.1 BROADER SEROTYPE COVERAGE AND INCREASING ADOPTION OF COMBINATION IMMUNIZATION SCHEDULES TO DRIVE MARKET
- 11.3 MONOVALENT VACCINES
- 11.3.1 ESTABLISHED SINGLE-DISEASE PROGRAMS AND EXPANDING ADULT IMMUNIZATION INDICATIONS TO SUPPORT MARKET
12 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION
- 12.1 INTRODUCTION
- 12.2 INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION
- 12.2.1 EASE OF ABSORPTION AND BETTER IMMUNE RESPONSE TO DRIVE ADOPTION
- 12.3 ORAL ADMINISTRATION
- 12.3.1 NEEDLE-FREE DELIVERY AND HIGH-VOLUME DISEASE-CONTROL CAMPAIGNS TO SUPPORT MARKET
- 12.4 OTHER ROUTES OF ADMINISTRATION
13 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER
- 13.1 INTRODUCTION
- 13.2 ADULT VACCINES
- 13.2.1 AGING POPULATIONS, BROADER ADULT INDICATIONS, AND GROWING LIFE-COURSE IMMUNIZATION TO DRIVE MARKET
- 13.3 PEDIATRIC VACCINES
- 13.3.1 EXPANDING CHILDHOOD IMMUNIZATION SCHEDULES AND NEW VACCINE INTRODUCTIONS TO DRIVE MARKET GROWTH
14 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION
- 14.1 INTRODUCTION
- 14.2 NORTH AMERICA
- 14.2.1 US
- 14.2.1.1 US to dominate North American market during forecast period
- 14.2.2 CANADA
- 14.2.2.1 Expansion of life-course immunization to support market growth
- 14.2.1 US
- 14.3 EUROPE
- 14.3.1 GERMANY
- 14.3.1.1 Adult immunization and updated national recommendations to drive market growth
- 14.3.2 UK
- 14.3.2.1 Expansion of adult and maternal immunization programs to support market growth
- 14.3.3 FRANCE
- 14.3.3.1 Favorable government initiatives for mass immunization to drive market
- 14.3.4 ITALY
- 14.3.4.1 Higher investments by companies for increased production capacities to drive market
- 14.3.5 SPAIN
- 14.3.5.1 Rising investments in vaccine development by private organizations to drive market
- 14.3.6 REST OF EUROPE
- 14.3.1 GERMANY
- 14.4 ASIA PACIFIC
- 14.4.1 CHINA
- 14.4.1.1 China to hold largest share of APAC vaccines market
- 14.4.2 JAPAN
- 14.4.2.1 Aging population and gradual expansion of routine vaccination to drive demand
- 14.4.3 INDIA
- 14.4.3.1 Large immunization requirements and manufacturing leadership to support strong growth
- 14.4.4 SOUTH KOREA
- 14.4.4.1 Strong government strategies for improved vaccine hubs to drive market
- 14.4.5 REST OF ASIA PACIFIC
- 14.4.1 CHINA
- 14.5 LATIN AMERICA
- 14.5.1 BRAZIL
- 14.5.1.1 Strong public procurement and domestic manufacturing to drive market
- 14.5.2 MEXICO
- 14.5.2.1 Trained workforce and ethnically varied population base for clinical trials to propel market growth
- 14.5.3 REST OF LATIN AMERICA
- 14.5.1 BRAZIL
- 14.6 MIDDLE EAST
- 14.6.1 GOVERNMENT-LED LOCALIZATION AND EXPANDING ADULT AND TRAVEL IMMUNIZATION TO SUPPORT MARKET GROWTH
- 14.7 AFRICA
- 14.7.1 HIGH UNMET IMMUNIZATION NEEDS AND LOCAL MANUFACTURING INITIATIVES TO DRIVE MARKET EXPANSION
15 COMPETITIVE LANDSCAPE
- 15.1 OVERVIEW
- 15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
- 15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN VACCINES MARKET
- 15.3 REVENUE ANALYSIS, 2021-2025
- 15.4 MARKET SHARE ANALYSIS, 2025
- 15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
- 15.5.1 STARS
- 15.5.2 EMERGING LEADERS
- 15.5.3 PERVASIVE PLAYERS
- 15.5.4 PARTICIPANTS
- 15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
- 15.5.5.1 Company footprint
- 15.5.5.2 Region footprint
- 15.5.5.3 Technology footprint
- 15.5.5.4 Type footprint
- 15.5.5.5 Route of administration footprint
- 15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
- 15.6.1 PROGRESSIVE COMPANIES
- 15.6.2 RESPONSIVE COMPANIES
- 15.6.3 DYNAMIC COMPANIES
- 15.6.4 STARTING BLOCKS
- 15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
- 15.6.5.1 Detailed list of key startups/SMEs
- 15.6.5.2 Competitive benchmarking of key startups/SMEs
- 15.7 COMPANY VALUATION & FINANCIAL METRICS
- 15.7.1 FINANCIAL METRICS
- 15.7.2 COMPANY VALUATION
- 15.8 PRODUCT COMPARISON
- 15.8.1 PRODUCT COMPARATIVE ANALYSIS
- 15.9 COMPETITIVE SCENARIO
- 15.9.1 PRODUCT LAUNCHES & APPROVALS
- 15.9.2 DEALS
- 15.9.3 EXPANSIONS
16 COMPANY PROFILES
- 16.1 KEY PLAYERS
- 16.1.1 PFIZER INC.
- 16.1.1.1 Business overview
- 16.1.1.2 Products offered
- 16.1.1.3 Recent developments
- 16.1.1.3.1 Product approvals
- 16.1.1.4 MnM view
- 16.1.1.4.1 Key strengths
- 16.1.1.4.2 Strategic choices
- 16.1.1.4.3 Weaknesses & competitive threats
- 16.1.2 GSK PLC
- 16.1.2.1 Business overview
- 16.1.2.2 Products offered
- 16.1.2.3 Recent developments
- 16.1.2.3.1 Product launches & approvals
- 16.1.2.3.2 Deals
- 16.1.2.3.3 Expansions
- 16.1.2.4 MnM view
- 16.1.2.4.1 Key strengths
- 16.1.2.4.2 Strategic choices
- 16.1.2.4.3 Weaknesses & competitive threats
- 16.1.3 MERCK & CO., INC.
- 16.1.3.1 Business overview
- 16.1.3.2 Products offered
- 16.1.3.3 Recent developments
- 16.1.3.3.1 Product approvals
- 16.1.3.3.2 Expansions
- 16.1.3.4 MnM view
- 16.1.3.4.1 Key strengths
- 16.1.3.4.2 Strategic choices
- 16.1.3.4.3 Weaknesses & competitive threats
- 16.1.4 SANOFI
- 16.1.4.1 Business overview
- 16.1.4.2 Products offered
- 16.1.4.3 Recent developments
- 16.1.4.3.1 Product approvals
- 16.1.4.3.2 Deals
- 16.1.4.3.3 Expansions
- 16.1.4.3.4 Other developments
- 16.1.4.4 MnM view
- 16.1.4.4.1 Key strengths
- 16.1.4.4.2 Strategic choices
- 16.1.4.4.3 Weaknesses & competitive threats
- 16.1.5 CSL
- 16.1.5.1 Business overview
- 16.1.5.2 Products offered
- 16.1.5.3 Recent developments
- 16.1.5.3.1 Product approvals
- 16.1.5.3.2 Deals
- 16.1.5.3.3 Expansions
- 16.1.6 EMERGENT
- 16.1.6.1 Business overview
- 16.1.6.2 Products offered
- 16.1.6.3 Recent developments
- 16.1.6.3.1 Product approvals
- 16.1.6.3.2 Deals
- 16.1.6.3.3 Other developments
- 16.1.7 JOHNSON & JOHNSON SERVICES, INC.
- 16.1.7.1 Business overview
- 16.1.7.2 Products offered
- 16.1.7.3 Recent developments
- 16.1.7.3.1 Deals
- 16.1.8 ASTRAZENECA
- 16.1.8.1 Business overview
- 16.1.8.2 Products offered
- 16.1.8.3 Recent developments
- 16.1.8.3.1 Deals
- 16.1.8.3.2 Expansions
- 16.1.9 SERUM INSTITUTE OF INDIA PVT. LTD.
- 16.1.9.1 Business overview
- 16.1.9.2 Products offered
- 16.1.9.3 Recent developments
- 16.1.9.3.1 Product launches & approvals
- 16.1.9.3.2 Deals
- 16.1.9.3.3 Expansions
- 16.1.10 BAVARIAN NORDIC
- 16.1.10.1 Business overview
- 16.1.10.2 Products offered
- 16.1.10.3 Recent developments
- 16.1.10.3.1 Product approvals
- 16.1.10.3.2 Deals
- 16.1.10.3.3 Other developments
- 16.1.11 TANABE PHARMA CORPORATION
- 16.1.11.1 Business overview
- 16.1.11.2 Products offered
- 16.1.11.3 Recent developments
- 16.1.11.3.1 Product launches & approvals
- 16.1.11.3.2 Deals
- 16.1.12 DAIICHI SANKYO COMPANY, LIMITED
- 16.1.12.1 Business overview
- 16.1.12.2 Products offered
- 16.1.12.3 Recent developments
- 16.1.12.3.1 Deals
- 16.1.13 PANACEA BIOTEC
- 16.1.13.1 Business overview
- 16.1.13.2 Products offered
- 16.1.13.3 Recent developments
- 16.1.13.3.1 Other developments
- 16.1.14 BIOLOGICAL E. LIMITED
- 16.1.14.1 Business overview
- 16.1.14.2 Products offered
- 16.1.14.3 Recent developments
- 16.1.14.3.1 Product approvals
- 16.1.14.3.2 Deals
- 16.1.14.3.3 Other developments
- 16.1.15 BHARAT BIOTECH
- 16.1.15.1 Business overview
- 16.1.15.2 Products offered
- 16.1.15.3 Recent developments
- 16.1.15.3.1 Product launches & approvals
- 16.1.15.3.2 Deals
- 16.1.16 NOVAVAX
- 16.1.16.1 Business overview
- 16.1.16.2 Products offered
- 16.1.16.3 Recent developments
- 16.1.16.3.1 Product approvals
- 16.1.16.3.2 Deals
- 16.1.17 INOVIO PHARMACEUTICALS
- 16.1.17.1 Business overview
- 16.1.17.2 Products offered
- 16.1.17.3 Recent developments
- 16.1.17.3.1 Other developments
- 16.1.1 PFIZER INC.
- 16.2 OTHER PLAYERS
- 16.2.1 SINOVAC
- 16.2.2 INCEPTA PHARMACEUTICALS LTD.
- 16.2.3 VALNEVA SE
- 16.2.4 EUBIOLOGICS CO., LTD.
- 16.2.5 BIO FARMA
- 16.2.6 MICROGEN
- 16.2.7 CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.
- 16.2.8 INDIAN IMMUNOLOGICALS LIMITED
17 RESEARCH METHODOLOGY
- 17.1 RESEARCH DATA
- 17.1.1 SECONDARY DATA
- 17.1.1.1 Key secondary sources
- 17.1.1.2 Key data from secondary research
- 17.1.2 PRIMARY DATA
- 17.1.2.1 Key primary participants
- 17.1.2.2 Breakdown of primary interviews
- 17.1.2.3 Key data from primary sources
- 17.1.1 SECONDARY DATA
- 17.2 MARKET SIZE ESTIMATION
- 17.2.1 GLOBAL VACCINES MARKET SIZE ESTIMATION, 2025
- 17.2.1.1 Approach 1: Company revenue analysis-based estimation (bottom-up approach)
- 17.2.1.2 Approach 2: Primary research
- 17.2.1.2.1 Key industry insights
- 17.2.1.3 Approach 3: Secondary analysis
- 17.2.1.4 Approach 4: Bottom-up approach (disease indication-based analysis)
- 17.2.1.5 Approach 5: MarketsandMarkets repository analysis
- 17.2.2 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH), 2025
- 17.2.1 GLOBAL VACCINES MARKET SIZE ESTIMATION, 2025
- 17.3 MARKET GROWTH RATE PROJECTIONS
- 17.4 DATA TRIANGULATION
- 17.5 RESEARCH ASSUMPTIONS
- 17.6 RESEARCH LIMITATIONS & RISK ASSESSMENT
18 APPENDIX
- 18.1 DISCUSSION GUIDE
- 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 18.3 CUSTOMIZATION OPTIONS
- 18.4 RELATED REPORTS
- 18.5 AUTHOR DETAILS
